Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S32006

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IndolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Agomelatine in the tree shrew model of depression: Effects on stress-induced nocturnal hyperthermia and hormonal status
The antidepressive drug agomelatine combines the properties of an agonist of melatonergic receptors 1 and 2 with an antagonist of… Expand
2013
2013
Serotonin2C Receptors and the Motor Control of Oral Activity
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in… Expand
  • table 1
2013
2013
Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's…
This study examined in naive or hemiparkinsonian rats the effect of various serotonin 2C (5-HT(2C)) receptor ligands differing in… Expand
2012
2012
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
The novel melatonergic agonist/5-HT(2C) antagonist agomelatine displays robust antidepressant properties in humans and is active… Expand
2011
2011
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
The novel antidepressant, agomelatine, behaves as an agonist at melatonergic receptors, and as an antagonist at edited, human… Expand
Highly Cited
2010
Highly Cited
2010
Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration
Abstract Objectives. The aim of this study was to investigate the acute modulation of the neurotrophin Brain-derived neurotrophic… Expand
Highly Cited
2010
Highly Cited
2010
Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
BackgroundAgomelatine is a melatonergic receptor agonist and a 5HT2C receptor antagonist that has shown antidepressant efficacy… Expand
  • figure 1
Highly Cited
2009
Highly Cited
2009
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist. In… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture
RationaleThe novel antidepressant, agomelatine, behaves as an agonist at melatonin MT1 and MT2 receptors and as an antagonist at… Expand
  • figure 4
Highly Cited
2008
Highly Cited
2008
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models
RationaleSerotonin (5-HT)2C receptors are implicated in the control of mood, and their blockade is of potential interest for the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE